Pegcetacoplan is a Synthetic Peptide owned by Apellis Pharmaceuticals, and is involved in 35 clinical trials, of which 21 were completed, 11 are ongoing, and 3 are planned.
Pegcetacoplan (APL-2) acts as complement factor C3 (C3) inhibitor. APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b. Complement 3 is a protein of the immune system that plays a key role in the complement system and contributes to innate immunity. The drug candidate acts as disease-modifying agent for PNH and AMD. Complement activation leads to formation of a structure called the membrane attack complex, which disrupts the membranes of target cells, leading to cell dysfunction and death. The therapeutic candidate binds tightly to complement component C3, preventing its participation in the complement activation cascade. Inhibition of complement C3, C3a anaphylatoxin, a mediator of local inflammatory process checks the disease progression.
The revenue for Pegcetacoplan is expected to reach a total of $49.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pegcetacoplan NPV Report.
Pegcetacoplan was originated by University of Pennsylvania and is currently owned by Apellis Pharmaceuticals. Swedish Orphan Biovitrum is the other company associated in development or marketing of Pegcetacoplan.
Pegcetacoplan (Empaveli, Aspaveli) is a synthetic peptide acts as a complement inhibitor. It is formulated as injectable solution for subcutaneous route of administration. Empaveli is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.
Pegcetacoplan (APL-2) is under development for the treatment of post-transplant recurrence of C3G or IC-MPGN, transplant-associated thrombotic microangiopathy (TA-TMA), IgA nephropathy (Berger's disease), lupus nephritis, primary membranous nephropathy, or C3 glomerulopathy (Kidney Disease (Nephropathy)) includes C3 glomerulonephritis, paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (advanced form of dry age-related macular degeneration) and autoimmune hemolytic anemia or cold agglutinin disease(wAIHA) and amyotrophic lateral sclerosis. It is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer. It is administered subcutaneously as an infusion for PNH and intravitreally for AMD. It is a compstatin derivative and a long-acting small cyclic peptide that targets complement factor C3. It was also under development for the treatment of kidney transplant rejection, refractory myasthenia gravis and neuromyelitis optica, neovascular age-related macular degeneration (AMD).
Apellis Pharmaceuticals Overview
Apellis Pharmaceuticals (Apellis), is a clinical-stage biopharmaceutical company that focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases through inhibition of the complement system at the level of C3 (central protein). Its pipeline product portfolio includes APL-2, a C3 inhibitor administered by intravitreal injections and subcutaneous injections for the treatment of geographic atrophy (GA), paroxysmal nocturnal hemoglobinuria (PNH), wet age-related macular degeneration (AMD), autoimmune hemolytic anemia (AIHA) and complement-dependent nephropathies. Apellis complement system activates C3 protein which enables immune responses such as opsonization, inflammation and formation of the membrane attack complex. It also conducts research on chronic therapy with a C3 inhibitor into clinical trials. The company operates with offices in the US, Ireland, Switzerland and Australia. Apellis is headquartered in Waltham, Massachusetts, the US.
The company reported revenues of (US Dollars) US$66.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 73.4% over FY2020. The operating loss of the company was US$636.9 million in FY2021, compared to an operating loss of US$213.7 million in FY2020. The net loss of the company was US$746.4 million in FY2021, compared to a net loss of US$344.9 million in FY2020. The company reported revenues of US$22.1 million for the third quarter ended September 2022, an increase of 35.1% over the previous quarter.
Quick View – Pegcetacoplan
|Highest Development Stage|